Response Genetics OverviewTrack Response Genetics's EBIT ($-13M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2015
Trailing 12 months ending Mar 31, 2015
As of the most recent data (March 2015), RGDXQ shows a EBIT of $-13M. That compares with $-10M in the prior-year period — down 26.5% year over year. That is above the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, RGDXQ's EBIT is now $-13M (was $-10M) — a 26.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Response Genetics is outperforming or lagging.
The its sector sector average EBIT is about $-63M. Response Genetics is at $-13M, which is higher that average. That is roughly 79.0% above the sector mean. Use the comparison chart on this page to see how RGDXQ stacks up against individual peers as well.
Tracking RGDXQ's ebit over time shows whether Response Genetics is scaling, shrinking, or reshaping that part of the business. The current reading is $-13M That compares with $-10M in the prior-year period — down 26.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Response Genetics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-13M) with ownership activity and broader fundamentals.
